Novo Nordisk A/S vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while iShares 10 20 Year Treasury Bond ETF trades at $97.83. The key difference: Novo Nordisk A/S pays a 3.63% dividend while iShares 10 20 Year Treasury Bond ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| NVO | TLH | |
|---|---|---|
Market Cap | $220.53B | — |
Sector | Health | Fixed Income |
52-Week High | $71.70 | $105.36 |
52-Week Low | $35.29 | $97.13 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | — |
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →